Technical Analysis for ZGNX - Zogenix, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | 2.62% | |
Pocket Pivot | Bullish Swing Setup | 2.62% | |
Volume Surge | Other | 2.62% | |
Calm After Storm | Range Contraction | 2.62% | |
Narrow Range Bar | Range Contraction | 2.62% | |
NR7 | Range Contraction | 2.62% | |
Parabolic Rise | Strength | 2.62% | |
Wide Bands | Range Expansion | 2.62% | |
Above Upper BB | Strength | 2.62% | |
Shooting Star Candlestick | Bearish | 2.93% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. |
Get a Trading Assistant
- Earnings date: 05/01/2022
Zogenix, Inc. Description
Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company's lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Pharmaceutical Pain Opioids Schizophrenia Chronic Pain Central Nervous System Disorders Nervous System Disorders Neurochemistry Migraine Morphinans Ketones Bipolar Disorder Headache Cell Signaling Retail Pharmacies Treatment Of Central Nervous System Disorders Treatment Of Migraine Hydrocodone Severe Chronic Pain Indoles Moderate To Severe Chronic Pain Pharmaceutical Distributors Relday Triptans
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 26.9 |
52 Week Low | 11.03 |
Average Volume | 3,180,751 |
200-Day Moving Average | 17.33 |
50-Day Moving Average | 22.56 |
20-Day Moving Average | 26.24 |
10-Day Moving Average | 26.26 |
Average True Range | 0.35 |
RSI | 77.73 |
ADX | 68.05 |
+DI | 46.84 |
-DI | 6.41 |
Chandelier Exit (Long, 3 ATRs) | 25.85 |
Chandelier Exit (Short, 3 ATRs) | 27.05 |
Upper Bollinger Bands | 26.51 |
Lower Bollinger Band | 25.97 |
Percent B (%b) | 1.32 |
BandWidth | 2.06 |
MACD Line | 0.93 |
MACD Signal Line | 1.21 |
MACD Histogram | -0.2786 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 27.27 | ||||
Resistance 3 (R3) | 27.27 | 27.09 | 27.17 | ||
Resistance 2 (R2) | 27.09 | 26.94 | 27.08 | 27.13 | |
Resistance 1 (R1) | 26.88 | 26.85 | 26.99 | 26.88 | 27.10 |
Pivot Point | 26.70 | 26.70 | 26.75 | 26.69 | 26.70 |
Support 1 (S1) | 26.49 | 26.55 | 26.60 | 26.49 | 26.26 |
Support 2 (S2) | 26.31 | 26.46 | 26.30 | 26.23 | |
Support 3 (S3) | 26.10 | 26.31 | 26.19 | ||
Support 4 (S4) | 26.10 |